BRCA1 antibody | MS110
| Mouse anti Human BRCA1 antibody, clone MS110 recognizes an epitope within the 304 amino acid N-Terminal (NT) region of human BRCA1, otherwise known as Breast cancer type 1 susceptibility protein, a tumor suppressor gene and major player in DNA damage repair, predominantly expressed in the nucleus during the S/G2 phase of the cell cycle.
Deleterious BRCA1 mutations corralate with increased risk of cancers in both males and females including breast, pancreatic and prostate cancer, although in males pancreatic and prostate cancer appear to be more strongly associated with BRCA2 gene mutations.
BRCA1 is a key marker of triple-negative breast cancer/TNBC (ER-/PR-/HER2-), a high risk aggressive cancer which makes up about 15% of invasive breast cancers, and which lacks the benefit of specific therapy that targets the three major proteins ER/PR/HER2. Triple-negative tumors are predominantly basal-like, poorly differentiated and of higher histological grade. Younger women have an increased rate of basal or BRCA related TNBC, compared with the higher proportion of apocrine, normal-like and rare subtypes of TNBC, seen in older women.
Mouse anti human BRCA1 antibody, clone MS110 is suitable for use in both immunohistochemical and immunofluorescence staining of human breast and ovarian tissue, and clone MS110 is widely used and reported (
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- TRIS-glycine buffered saline, NaCl
- Preservative Stabilisers
- <0.1% sodium azide (NaN3)
- Recombinant protein corresponding to the N-Terminal region of human BRCA1.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunized mice were fused with cells of the mouse NSI myeloma cell line.
- For research purposes only
- 12 months from date of despatch
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen 1|
|Immunohistology - Paraffin 2|
- 1 This product requires antigen retrieval using heat treatment prior to staining of frozen sections. Sodium citrate buffer pH 6.0 is recommended for this purpose. See Yoshikawa, K.et al. for details.
- 2 This product requires antigen retrieval using heat treatment prior to staining of paraffin sections. Sodium citrate buffer pH 6.0 is recommended for this purpose. See Yoshikawa, K.et al. for details.
- Histology Positive Control Tissue
- Human breast carcinoma
- Western Blotting
- Mouse anti Human BRCA1 antibody, clone MS110 detects a band of approximately 220kDa in HeLa nuclear extract. A smaller band of 85kDa may also be seen, which may represent post-translational modification.
References for BRCA1 antibody
Scully, R. et al. (1996) Location of BRCA1 in human breast and ovarian cancer cells.
Science. 272 (5258): 123-6.
Yoshikawa, K. et al. (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Clin Cancer Res. 5 (6): 1249-61.
Scully, R. et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells.
Cell. 88: 265-75.
Chen, J. (2000) Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.
Cancer Res. 60: 5037-9.
Fraser, J.A. et al. (2003) A role for BRCA1 in sporadic breast cancer.
Br J Cancer. 88: 1263-70.
Kleiman, F.E. et al. (2005) BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II.
Genes Dev. 19: 1227-37.
Pageau, G.J. and Lawrence, J.B. (2006) BRCA1 foci in normal S-phase nuclei are linked to interphase centromeres and replication of pericentric heterochromatin.
J Cell Biol. 175: 693-701.
Milner, R. et al. (2013) Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours.
Virchows Arch. 462 (3): 269-79.
- Breast Cancer Type 1 Susceptibility Protein
- Entrez Gene
- GO Terms
- GO:0007059 chromosome segregation
- GO:0005515 protein binding
- GO:0000724 double-strand break repair via homologous recombination
- GO:0003677 DNA binding
- GO:0003713 transcription coactivator activity
- GO:0003723 RNA binding
- GO:0030529 ribonucleoprotein complex
- GO:0006915 apoptosis
- GO:0004842 ubiquitin-protein ligase activity
- View More GO Terms
- GO:0005654 nucleoplasm
- GO:0006301 postreplication repair
- GO:0006359 regulation of transcription from RNA polymerase III promoter
- GO:0006633 fatty acid biosynthetic process
- GO:0006978 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator
- GO:0007049 cell cycle
- GO:0008270 zinc ion binding
- GO:0008274 gamma-tubulin ring complex
- GO:0008630 DNA damage response, signal transduction resulting in induction of apoptosis
- GO:0042802 identical protein binding
- GO:0010212 response to ionizing radiation
- GO:0010552 positive regulation of gene-specific transcription from RNA polymerase II promoter
- GO:0015631 tubulin binding
- GO:0016481 negative regulation of transcription
- GO:0016563 transcription activator activity
- GO:0030521 androgen receptor signaling pathway
- GO:0031398 positive regulation of protein ubiquitination
- GO:0031436 BRCA1-BARD1 complex
- GO:0031572 G2/M transition DNA damage checkpoint
- GO:0031625 ubiquitin protein ligase binding
- GO:0042127 regulation of cell proliferation
- GO:0043627 response to estrogen stimulus
- GO:0045717 negative regulation of fatty acid biosynthetic process
- GO:0045739 positive regulation of DNA repair
- GO:0046600 negative regulation of centriole replication
- GO:0050681 androgen receptor binding
- GO:0051865 protein autoubiquitination
- GO:0070531 BRCA1-A complex
- GO:0071681 cellular response to indole-3-methanol
- GO:0085020 protein K6-linked ubiquitination
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up